Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Their objective was to determine the effects of physiological GH replacement on cardiovascular risk markers and body composition in women with GH deficiency (GHD).

Study participants were randomized to receive GH (goal mid-normal serum IGF-1) or placebo.

Why It Was Studied

There are no randomized, placebo-controlled studies of physiological GH therapy solely in women.

Who Took Part

The abstract describes 43 women taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, women only.

43 women with GHD due to hypopituitarism were included in the study.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the women nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

Some women received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

This was a 6-month, randomized, placebo-controlled, double-blind study.

The study was conducted at the General Clinical Research Center.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Body Composition, Cardiovascular Diseases, Glucose, Growth Hormone, Human Growth Hormone and Hypopituitarism.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 43 women.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.